Drugs / MenABCWY
MenABCWY
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 29 trials | ||||||
| Phase 2 | NCT05087056 | Nov 2021 → Mar 2027 expected | meningococcal meningitis | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04645966 | Nov 2020 → Sep 2022 | meningococcal infection | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT04440176 | Jun 2020 → Jan 2024 | meningococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT03587207 | Jul → Dec 2018 | meningococcal meningitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02946385 | Nov 2016 → Feb 2018 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02212457 | Aug 2014 → May 2015 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02140762 | May → Nov 2014 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT01272180 | Aug → Oct 2011 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT01367158 | Jul 2011 → Jan 2012 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04502693 | Aug 2020 → Sep 2022 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT04440163 | Jun 2020 → Jul 2022 | meningococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT03135834 | Apr 2017 → Oct 2022 | meningococcal infection | Pfizer | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-12-28 | Pfizer | U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents pfizer.com ↗ |
| 2022-09-15 | Pfizer | Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents pfizer.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenABCWY | “A third MenABCWY vaccine dose induced robust immune responses against vaccine antigens, although antibody levels 6 months later were comparable with those observed 5 months...” PMID 26135245 ↗ Oct 201510“An investigational combined serogroups ABCWY vaccine (MenABCWY) was developed to protect against clinically important Neisseria meningitidis serogroups.” PMID 29329168 ↗ May 2018 |
| Known as | GSK3536819A | “The purpose of this study is to assess the safety, tolerability, and immunogenicity of the combined meningococcal groups A, B, C, W and Y (MenABCWY) vaccine (GSK3536819A)...” NCT05087056 ↗1“of 2 doses of GSK's investigational combined meningococcal (MenABCWY) vaccine (GSK3536819A) in healthy adolescents and young adults.” NCT04502693 ↗ |
| Known as | Meningococcal ABCWY Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02946385 ↗ |
| Known as | PenbrayaTM | “pentavalent MenABCWY vaccine (PenbrayaTM)” PMID 42042828 ↗ Apr 2026 |
| Modality | Vaccine | “An investigational combined serogroups ABCWY vaccine (MenABCWY) was developed to protect against clinically important Neisseria meningitidis serogroups.” PMID 29329168 ↗ May 2018 |
| Route | Intramuscular | “0.5 mL MenABCWY vaccine (intramuscular (IM) injection)” NCT02140762 ↗ |